• Jade Biosciences posted a Q1 net loss of $40.4 million, compared with a $38.2 million loss a year earlier.
• R&D expense climbed to $36.1 million from $20 million, while G&A costs rose to $7.4 million from $3.4 million.
• Cash, cash equivalents, investments totaled $311.3 million as of March 31, with runway expected into first-half 2028.
• Phase 2 trial of lead IgA nephropathy candidate JADE101 expected to start in Q2, with interim data expected in 2027; interim biomarker-rich Phase 1 data set for an oral presentation at the European Renal Association Congress.
• Phase 1 study of JADE201 in rheumatoid arthritis expected to begin in Q2 with interim data expected in 2027, while JADE301 first-in-human trial remains on track for first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071605PRIMZONEFULLFEED9714859) on May 07, 2026, and is solely responsible for the information contained therein.